CAMARO CHEVY 1967 1969 1982 1993 17 BROCHURE CHEVROLET / POSTER 500 INDY 22 x Sales Brochures


  1. Home
  2. CAMARO CHEVY 1967 1969 1982 1993 17 BROCHURE CHEVROLET / POSTER 500 INDY 22 x
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
1993 1982 1969 1967 CHEVY CAMARO 17 x 22 INDY 500 POSTER / CHEVROLET BROCHURE
published on tue nov 09 2021

CAMARO CHEVY 1967 1969 1982 1993 17 BROCHURE CHEVROLET / POSTER 500 INDY 22 x Sales Brochures

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

CAMARO CHEVY 1967 1969 1982 1993 17 BROCHURE CHEVROLET / POSTER 500 INDY 22 x Sales Brochures

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS